Gout There are some limited studies in patients with gout, some reporting a possible flare of gout when therapy with GLP1 is started, mostly due to rapid weight loss and dehydration that may precipitate gout attacks
SURMOUNT-MAINTAIN (Horn 2026, 112 weeks): continued top dose -21.9% vs 5 mg step-down -16.6% vs placebo -9.9%, rescue therapy 8/25/67%: Aronne JAMA 2024
Forests 10, 1090
Best choice: Both, depending on whether you need stronger detox/antioxidant support (glutathione) or immune modulation and resilience (NAC)
The largest trial involving DSIP to date, which included a total of 107 volunteers, reported that the peptide was generally well-tolerated with mostly minor side effects, which included [8]: Low blood pressure Increased sweating Headache Nausea Vertigo Considering that the drop in blood pressure was reported as moderate to severe in some patients, researchers should consider hypotension as a potentially exclusionary criterion for DSIP research
doi: 10.3389/FMICB.2021.700605 11 AtanaseL